{"slideshow_credits": null, "snippet": "Mr. Shkreli, a former Turing chief executive who has been criticized over drug pricing, was called to appear for a hearing to discuss pricing trends.", "abstract": "Turing Pharmaceuticals founder Martin Shkreli is served subpoena to appear before House Committee on Oversight and Government Reform to discuss pricing trends and other developments in drug industry; it is unclear whether Shkreli, who has been charged with securities fraud, will show up to testify.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [{"firstname": "Matthew", "role": "reported", "lastname": "GOLDSTEIN", "rank": 1, "organization": ""}], "original": "By MATTHEW GOLDSTEIN", "contributor": "Andrew Pollack contributed reporting."}, "web_url": "http://www.nytimes.com/2016/01/21/business/dealbook/congress-subpoenas-martin-shkreli-over-drug-prices.html", "lead_paragraph": "Mr. Shkreli, a former Turing chief executive who has been criticized over drug pricing, was called to appear for a hearing to discuss pricing trends.", "headline": {"main": "Congress Calls Martin Shkreli to Testify on Rapid Rises in Drug Pricing", "print_headline": "Congress Calls Shkreli to Testify on Rapid Rises in Drug Pricing"}, "_id": "569fe66a38f0d80627b20ab9", "word_count": "848", "multimedia": [{"height": 126, "url": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 447, "url": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-articleLarge.jpg", "legacy": {"xlarge": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "447"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/01/21/business/21Shkrelisub/21Shkrelisub-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2016-01-21T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Turing Pharmaceuticals AG", "is_major": "Y", "rank": "1"}, {"name": "persons", "value": "Shkreli, Martin (1983- )", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "3"}, {"name": "organizations", "value": "House Committee on Oversight and Government Reform", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Prices (Fares, Fees and Rates)", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Securities and Commodities Violations", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}